Researchers at Grail, a healthcare technology company, have developed a new blood test called Galleri that can detect more than 50 types of cancer, even before symptoms appear. The test is still in the early stages of development, but it has the potential to revolutionize cancer screening and early detection.
Galleri works by detecting tiny fragments of cancer DNA that are shed into the bloodstream by tumors. The test is able to identify the cancer signal and predict where in the body the cancer may have originated.
In a clinical study of over 6,600 participants, Galleri was able to detect cancer in 52 participants who did not have any symptoms. Of these 52 participants, 45 had cancers that are not currently routinely screened for, such as pancreatic cancer and ovarian cancer.
The study also found that Galleri was able to detect cancer early, before it had spread to other parts of the body. This means that early treatment could be initiated, which could improve the chances of survival.
Galleri is not yet available to the public, but Grail is planning to launch the test in the United States in 2023. The company is also working to expand the test to other countries.
The development of Galleri is a significant breakthrough in cancer screening and early detection. The test has the potential to save lives by detecting cancer early, when it is most treatable.
How does Galleri work?
Galleri is a liquid biopsy test, which means that it analyzes DNA fragments that are shed into the bloodstream by tumors. The test uses a next-generation sequencing (NGS) platform to identify these DNA fragments and to determine where in the body the cancer may have originated.
What types of cancer can Galleri detect?
Galleri can detect more than 50 types of cancer, including:
- Breast cancer
- Colorectal cancer
- Esophageal cancer
- Head and neck cancer
- Lung cancer
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Stomach cancer
How accurate is Galleri?
In the clinical study mentioned above, Galleri was able to detect cancer in 52 participants who did not have any symptoms. Of these 52 participants, 45 had cancers that are not currently routinely screened for.
The test also had a very low false-positive rate, meaning that it rarely gave a positive result for cancer in people who did not have cancer.
When will Galleri be available?
Grail is planning to launch Galleri in the United States in 2023. The company is also working to expand the test to other countries.
What is the cost of Galleri?
The cost of Galleri has not yet been announced.
How can I get a Galleri test?
Galleri is not yet available to the public. Once the test is launched, it will be available through select healthcare providers.
Galleri has the potential to revolutionize cancer screening and early detection. By detecting cancer early, the test could save lives.
